Effects of linagliptin vs glimepiride stratified by prior insulin secretagogue use in the cardiovascular outcome study of linagliptin versus glimepiride in type 2 diabetes (CAROLINA) trial

Back

ESC Premium Access

Effects of linagliptin vs glimepiride stratified by prior insulin secretagogue use in the cardiovascular outcome study of linagliptin versus glimepiride in type 2 diabetes (CAROLINA) trial

Session: Improving Cardiovascular Function and Clinical Outcome in Diabetes Using New Guideline-Based Pharmacotherapy

Topic: Antidiabetic Pharmacotherapy

Speaker: Professor D. McGuire (Dallas, US)

Event: ESC Congress 2020

Congress Presentation

About the speaker

Professor Darren Keith McGuire

University of Texas Southwestern Medical Center, Dallas (United States of America)

18 presentations

0 follower

7 more presentations in this session

Dulaglutide is cardioprotective with or without background metformin in patients with diabetes and established or high risk for coronary vascular disease. A subgroup analysis of the REWIND Trial.

Speaker: Doctor G. Ferrannini (Stockholm, SE)

Cardiovascular outcomes in patients with type 2 diabetes and reduced eGFR and albuminuria: a REWIND post hoc subgroup analysis

Speaker: Professor H. Colhoun (Edinburgh, GB)

Direct effects of canagliflozin on human myocardial redox signalling: a novel role for SGLT1 inhibition

Speaker: Doctor H. Kondo (Yufu City, JP)

Impact of polyvascular disease and renal dysfunction on cardiovascular outcomes in diabetes: post hoc analyses from EMPA-REG OUTCOME

Speaker: Professor S. Verma (Toronto, CA)

Natriuretic effect of 2 weeks of dapagliflozin treatment in patients with type 2 diabetes and preserved kidney function: results of the DAPASALT trial

Speaker: Professor H. Heerspink (Groningen, NL)

Access the full session

Improving Cardiovascular Function and Clinical Outcome in Diabetes Using New Guideline-Based Pharmacotherapy

Speakers: Professor D. McGuire, Doctor G. Ferrannini, Professor H. Colhoun, Doctor H. Kondo, Professor S. Verma...

Access

About the event

ESC Congress 2020

29 August - 1 September 2020

Sessions Presentations

Congress

Effects of linagliptin vs glimepiride stratified by prior insulin secretagogue use in the cardiovascular outcome study of linagliptin versus glimepiride in type 2 diabetes (CAROLINA) trial

About the speaker

Professor Darren Keith McGuire

7 more presentations in this session

Dulaglutide is cardioprotective with or without background metformin in patients with diabetes and established or high risk for coronary vascular disease. A subgroup analysis of the REWIND Trial.

Cardiovascular outcomes in patients with type 2 diabetes and reduced eGFR and albuminuria: a REWIND post hoc subgroup analysis

Direct effects of canagliflozin on human myocardial redox signalling: a novel role for SGLT1 inhibition

Impact of polyvascular disease and renal dysfunction on cardiovascular outcomes in diabetes: post hoc analyses from EMPA-REG OUTCOME

Natriuretic effect of 2 weeks of dapagliflozin treatment in patients with type 2 diabetes and preserved kidney function: results of the DAPASALT trial

Access the full session

Improving Cardiovascular Function and Clinical Outcome in Diabetes Using New Guideline-Based Pharmacotherapy

About the event

ESC Congress 2020

ESC 365 is supported by